These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31311315)

  • 1. The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells.
    van der Bent ML; Paulino da Silva Filho O; Willemse M; Hällbrink M; Wansink DG; Brock R
    FASEB J; 2019 Oct; 33(10):11314-11325. PubMed ID: 31311315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.
    Lee JE; Bennett CF; Cooper TA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(11):4221-6. PubMed ID: 22371589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.
    Stoodley J; Miraz DS; Jad Y; Fischer M; Wood MJA; Varela MA
    Methods Mol Biol; 2023; 2587():209-237. PubMed ID: 36401033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting nuclear RNA for in vivo correction of myotonic dystrophy.
    Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA
    Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
    De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.
    Ait Benichou S; Jauvin D; De Serres-Bérard T; Bennett F; Rigo F; Gourdon G; Boutjdir M; Chahine M; Puymirat J
    Hum Gene Ther; 2022 Aug; 33(15-16):810-820. PubMed ID: 35794764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.
    Gao Z; Cooper TA
    Hum Gene Ther; 2013 May; 24(5):499-507. PubMed ID: 23252746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
    Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
    Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
    Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
    Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliable and versatile immortal muscle cell models from healthy and myotonic dystrophy type 1 primary human myoblasts.
    Pantic B; Borgia D; Giunco S; Malena A; Kiyono T; Salvatori S; De Rossi A; Giardina E; Sangiuolo F; Pegoraro E; Vergani L; Botta A
    Exp Cell Res; 2016 Mar; 342(1):39-51. PubMed ID: 26905645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic development in myotonic dystrophy].
    Takahashi MP; Nakamori M; Mochizuki H
    Rinsho Shinkeigaku; 2014; 54(12):1077-9. PubMed ID: 25519965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
    Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
    Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
    Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
    Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.
    Carrell ST; Carrell EM; Auerbach D; Pandey SK; Bennett CF; Dirksen RT; Thornton CA
    Hum Mol Genet; 2016 Oct; 25(19):4328-4338. PubMed ID: 27522499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.
    Pandey SK; Wheeler TM; Justice SL; Kim A; Younis HS; Gattis D; Jauvin D; Puymirat J; Swayze EE; Freier SM; Bennett CF; Thornton CA; MacLeod AR
    J Pharmacol Exp Ther; 2015 Nov; 355(2):329-40. PubMed ID: 26330536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Determination of MBNL1 Protein Levels by Quantitative Dot Blot for the Evaluation of Antisense Oligonucleotides in Myotonic Dystrophy Myoblasts.
    Moreno N; González-Martínez I; Artero R; Cerro-Herreros E
    Methods Mol Biol; 2022; 2434():207-215. PubMed ID: 35213019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of trinucleotide repeat sequences in myotonic dystrophy cells using a single fluorochrome-labeled PNA probe.
    Taneja KL
    Biotechniques; 1998 Mar; 24(3):472-6. PubMed ID: 9526660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery.
    Mondragon-Gonzalez R; Perlingeiro RCR
    Dis Model Mech; 2018 Jul; 11(7):. PubMed ID: 29898953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
    Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
    Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
    Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
    Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.